
Sign up to save your podcasts
Or


The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:
1. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial. JAMA 2026. Discussion by:
Guest:
Jessica Stieritz, MD
Resident - Abington Family Medicine Residency Program
Jefferson Health
2. A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomized controlled trial. Lancet Rheumatology 2026. Discussion by:
Guest:
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College Thomas Jefferson University
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington
3. Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients. NEJM 2026 Discussion by:
Guest:
Steven Leonard, MD
Resident - Abington Family Medicine Residency Program
Jefferson Health
Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.
This Podcast Episode does not offer CME/CE Credit.
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
By NACE4.6
2121 ratings
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:
1. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial. JAMA 2026. Discussion by:
Guest:
Jessica Stieritz, MD
Resident - Abington Family Medicine Residency Program
Jefferson Health
2. A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomized controlled trial. Lancet Rheumatology 2026. Discussion by:
Guest:
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College Thomas Jefferson University
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington
3. Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients. NEJM 2026 Discussion by:
Guest:
Steven Leonard, MD
Resident - Abington Family Medicine Residency Program
Jefferson Health
Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.
This Podcast Episode does not offer CME/CE Credit.
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

978 Listeners

321 Listeners

701 Listeners

124 Listeners

141 Listeners

101 Listeners

298 Listeners

264 Listeners

3,374 Listeners

1,150 Listeners

404 Listeners

95 Listeners